Right to Manufacture Commercial Supply Sample Clauses

Right to Manufacture Commercial Supply. 19 ARTICLE 8 PAYMENTS ..................................................... 20 8.1 Technology Access Fee ........................................... 20 8.2
Sample 1
AutoNDA by SimpleDocs
Right to Manufacture Commercial Supply. In the event that BMS has entered into a Development and Commercialization Agreement or exercised its BMS Option for a particular Product, BMS will have the first right to manufacture and supply such Product or the Compound contained in such Product at any time thereafter for clinical and commercial use, as applicable. In the event that BMS does not enter into a Development and Commercialization Agreement or exercise its BMS Option for a particular Product, and Vanda enters into negotiations with a Third Party to manufacture a clinical or commercial supply of such Product or the Compound contained in such Product (the "Supply Agreement"), it will promptly notify BMS and provide a reasonably detailed summary of the material financial terms of such Supply Agreement as well as a reasonably detailed summary of data pertinent to evaluating such opportunity. BMS will have thirty (30) days from receipt of the data summary to notify Vanda that it will enter into the agreement on the same material financial terms and conditions. The Parties will then negotiate a Supply Agreement in good faith for thirty (30) days or such longer period as agreed between the Parties. In the event the Parties do not enter into a Supply Agreement within such thirty (30) day period, or the agreed extension thereof, Vanda is free to enter into an agreement with any other entity with respect to such clinical or commercial supply.
Sample 1
Right to Manufacture Commercial Supply. In the event that BMS has entered into a Development and Commercialization Agreement or exercised its BMS Option for a particular Product, BMS will have the first right to manufacture and supply such Product or the Compound contained in such Product at any time thereafter for clinical and commercial use, as applicable. In the event that BMS does not enter into a Development and Commercialization Agreement or exercise its BMS Option for a particular Product, and Vanda enters into negotiations with a Third Party to manufacture a clinical or commercial supply of such Product or the Compound contained in such Product (the "Supply Agreement"), it will promptly notify BMS and provide [*]. BMS will have [*] from receipt of the data summary to notify Vanda that it will [*]. The Parties will then negotiate a Supply Agreement in good faith for [*] or such longer period as agreed between the Parties. In the event the Parties do not enter into a Supply Agreement within such [*] period, or the agreed extension thereof, Vanda is free to enter into an agreement with any other entity with respect to such clinical or commercial supply.
Sample 1

Related to Right to Manufacture Commercial Supply

  • Commercial Supply Celgene shall Manufacture and supply all Commercial Supplies.

  • Manufacture (a) Manufacturer shall only manufacture the specific number of Products as requested by Company and at no time shall manufacture excess goods or overruns. Manufacturer shall not sell any Products bearing the Trademarks to any third parties without the express written consent of Company.

  • Clinical Supply Takeda will provide to Licensee[***] the amount of TAK-385 Licensed Compound or TAK-385 Licensed Products needed by Licensee to complete all Clinical Trials contemplated by the TAK-385 Development Plan (estimated by Licensee as of the Effective Date to be [***]), solely to the extent that Takeda can supply such TAK-385 [***] = Portions of this exhibit have been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment requested under 17 C.F.R. Sections 200.80(b)(4) and 230.406. Licensed Compound or TAK-385 Licensed Products (a) from its supply of TAK-385 Licensed Compound or TAK-385 Licensed Products in existence as of the Effective Date and which supply can be used for its intended purposes without further re-processing (the “Initial Clinical Supply”) and (b) after retaining the amount needed by Takeda for Clinical Trials in the Takeda Territory. Takeda will also provide to Licensee, at [***] any additional supplies of TAK-385 Licensed Compound or TAK-385 Licensed Products in excess of the Initial Clinical Supply needed by Licensee to complete all Clinical Trials contemplated by the TAK-385 Development Plan. Within [***] days after the Effective Date, the Parties will enter into a manufacturing and supply agreement (the “Takeda Clinical Manufacturing and Supply Agreement”), which will govern the terms and conditions of the Manufacturing and supply of the TAK-385 Licensed Compound and TAK-385 Licensed Products (including the Initial Clinical Supply) by Takeda to Licensee for Development purposes, including the exact quantities and the timelines for delivery. The Parties will negotiate the terms and conditions of such Takeda Clinical Manufacturing and Supply Agreement in good faith for a period of [***] days (as may be extended upon agreement of the Parties). As part of the negotiation related to the Takeda Clinical Manufacturing and Supply Agreement, the Parties shall discuss in good faith the ability of Takeda to supply to Licensee [***]. If the Parties have not entered into a definitive agreement within such negotiation period, then the final terms and conditions of such agreement will be resolved in accordance with Section 8.2 (Arbitration for Failure to Agree).

  • Product The term “

  • Development of Products (a) During the term of this Agreement, ViewRay may from time to time seek services from PEKO with respect to the development of certain Products that can be incorporated into the ViewRay Renaissance™ MRI-guided radiation therapy system. For each Program to be undertaken by PEKO pursuant to this Agreement, the parties will prepare a “Work Statement” and agree to said “Work Statement” in substantially the form attached as Attachment 1. Each Work Statement will describe: (i) the (i) services that PEKO will be responsible for providing to ViewRay and the deliverables that PEKO will be responsible for delivering to ViewRay (“Deliverable(s)”), (ii) delivery schedule for the Deliverables, (iii) pricing terms, (iv) work plan for the Program, and (v) ViewRay’s responsibilities in connection with the Program. Each Work Statement will be prepared based upon the requirements and information provided to PEKO by ViewRay. A separate Work Statement will be required for each Program; and each Work Statement will become subject to this Agreement only when mutually agreed and signed by ViewRay and PEKO.

  • API A. Reliant shall supply to Cardinal Health for Manufacturing and Packaging, at Reliant’s sole cost, the API and applicable reference standards in quantities sufficient to meet Reliant’s requirements for each Product as further set forth in Article 4. Prior to delivery of any of the API or reference standard to Cardinal Health for Manufacturing and Packaging, Reliant shall provide to Cardinal Health a copy of the API Material Safety Data Sheet (“MSDS”), as amended, and any subsequent revisions thereto. Reliant shall supply the API, reference standards, and Certificate of Analysis FOB the Facility no later than thirty (30) days before the scheduled Manufacture Date upon which such API will be used by Cardinal Health. Upon receipt of the API, Cardinal Health shall conduct identification testing of the API. Cardinal Health shall use the API solely and exclusively for Manufacturing and Packaging under this Agreement. The maximum volume of API that Reliant supplies to Cardinal Health shall not exceed the amount reflected in the Firm Commitment and the next six (6) months of the Rolling Forecast.

  • Licensed Products Lessee will obtain no title to Licensed Products which will at all times remain the property of the owner of the Licensed Products. A license from the owner may be required and it is Lessee's responsibility to obtain any required license before the use of the Licensed Products. Lessee agrees to treat the Licensed Products as confidential information of the owner, to observe all copyright restrictions, and not to reproduce or sell the Licensed Products.

  • Supply of Product The JDC shall be responsible for determining the sources of, and arrangements for, the manufacture and supply of Products that the JDC believes will result in long-term profit maximization for such Products. The JDC shall endeavor to [ * ].

  • Supply of Products TheraSense shall be responsible for the ------------------ manufacture of FreeStyle Products for sale to Nipro.

  • Manufacture of Products All Products marketed through Grantor's Web ------------------------- Site shall be manufactured, packaged, prepared, and shipped in accordance with the specifications and requirements described on Exhibit A hereto as it may be modified from time to time. Quality control standards relating to the Product's weight, color, consistency, micro-biological content, labeling and packaging are also set forth on Exhibit A. In the event that Exhibit A is incomplete, Products shall be manufactured and shipped in accordance with industry standards.

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!